
Pulse Biosciences rose 237.2% from $13.75 to $46.36, ahead of the S&P 500's +11.2%. Its worst day was Feb 20 (−14.6%), and its low came Nov 20 at $12.66.
Story events cover the past 12 months · Times ET
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Pulse Biosciences closed at its lowest level of the year, 7.9% below where the year started.
−2.7% · S&P 500 −1.5%
Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months
+51.6%, the year's best day, on 3M shares, the year's heaviest volume · S&P 500 +1.9%
EPS of $-0.26 missed the $-0.25 estimate on $264,000.00 revenue (est. $250,000.00).
−14.6%, the year's worst day · S&P 500 +0.7%
EPS of $-0.27 missed the $-0.24 estimate on $401,000.00 revenue (est. $420,000.00).
−3.8% · S&P 500 −0.4%
Pulse Biosciences shares rose 22.1%, while the S&P 500 fell 0.2%.
+22.1% · S&P 500 −0.2%
EPS of $-0.36 missed the $-0.29 estimate on $434,000.00 revenue (est. $566,664.00).
+10.9% · S&P 500 +0.6%
EPS of $-0.32 missed the $-0.30 estimate on $395,000.00 revenue (est. $517,336.00).
+0.4% · S&P 500 +0.3%
Where it ended: a close of $46.36 on Nov 16, 2026. Up next: Q4 2026 earnings on Feb 18, 2027 (EPS est. $-0.29, revenue est. $598,000.00).
Nothing in the past 12 months.
All PLSE dividend history